Biomarker ID | 1616 |
PMID | 31035590 |
Year | 2019 |
Biomarker | SMAD3 [SNP: rs9302242; A vs G] |
Biomarker Basis | Mutation Based |
Biomolecule | Mutation |
Source | Blood |
Subjects | Humans |
Regulation | NA |
Odds Ratio/Hazard Ratio/Relative Risk | HR: 2.03 (95% CI: 1.24–3.32) |
Effect on Pathways | Pathways include: NF-kappaB activation by non-typeable Hemophilus influenzae, Integrated cancer pathway, Androgen receptor signaling, proteolysis, and transcription regulation, Myc active pathway,Transcriptional activity of SMAD2/SMAD3-SMAD4 heterotrimer |
Experiment | Biochemical recurrence Vs No Biochemical Recurrence |
Type of Biomarker | Prognostic |
Cohort | 418 patients in the training cohort (80 experiencing Biochemical Recurrence) and 131 patients in the validation cohort (28 experiencing Biochemical Recurrence) were chosen for the study |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | p=0.005 |
Method Used | Allele specific PCR |
Clinical | No |
Remarks | NA |
Clinical Trial Number | NA |
Degree Of Validity | Validated on independent patient dataset |
Technical Name | NA |